CompletedPhase 1NCT02873260
Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
Studying Dengue fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Anna Durbin, MD, MDCenter for Immunization Research (CIR), Johns Hopkins School of Public Health
- Intervention
- TetraVax-DV-TV005(biological)
- Enrollment
- 48 enrolled
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2016 – 2017
Study locations (2)
- Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
- University of Vermont Testing Center, Burlington, Vermont, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02873260 on ClinicalTrials.govOther trials for Dengue fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06891950Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)Butantan Institute
- RECRUITINGNANCT07412483A Controlled Human Infection Model of DengueTan Tock Seng Hospital
- RECRUITINGPHASE3NCT06579755A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)Takeda
- RECRUITINGNCT07409857International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)Mahidol University
- ACTIVE NOT RECRUITINGPHASE3NCT07047521A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy AdultsTakeda
- ENROLLING BY INVITATIONPHASE2NCT07172100To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated ThrombocytopeniaZiauddin Hospital
- RECRUITINGPHASE2NCT06551844Adaptive Dengue Antiviral Platform TrialOxford University Clinical Research Unit, Vietnam
- RECRUITINGNCT07007585Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus InfectionJose Ivan Rodriguez de Molina Serrano